

# Advancing immunodiagnostics through surface chemistry modification

NWR Virtual Healthcare  
Conference

26 March 2026

Merrill Gray, MD/CEO



# Disclaimer



## **IMPORTANT INFORMATION**

The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

## **FORWARD-LOOKING STATEMENTS**


The presentation may contain certain “forward-looking statements”. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding AnteoTech's intent, belief or current expectations with respect to AnteoTech’s business and operations, market conditions, results of operations and financial condition, capital adequacy and risk management. These forward-looking statements should not be relied upon as a representation or warranty, express or implied, as to future matters. Prospective financial information has been based on current expectations about future events and is, however, subject to risks, uncertainties, contingencies and assumptions that could cause actual results to differ materially from the expectations described in such prospective information. AnteoTech disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date of the presentation, subject to the disclosure requirements applicable to the Group.

## **NOT AN OFFER OF SECURITIES**

This presentation should not be relied on as a recommendation or forecast by AnteoTech. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account your financial objectives, situation or needs. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any investment decision.


AnteoBind™ is a trademark of AnteoTech. The use of registered trademark symbols in relation to the various product names is implied throughout this presentation. All \$ amounts are quoted in USD unless otherwise stated.

# Agenda



- **AnteoTech Limited (ASX:ADO) Overview**
- **Life Sciences markets overview**
- **Our Diagnostic Applications**
- **How AnteoBind™ works**
- **Progress Update**
- **Our customers and partners**
- **Summary**

# Business Overview (ASX:ADO)



A chemical and materials business

Specialising in surface chemistry modification

Delivering molecular-level “cross-linking” (molecule-to-molecule and molecule to surface) solutions


Bioconjugation in diagnostics is our Life Sciences focus

# Life Sciences Markets: An Overview

AnteoTech currently does not operate in these Life Sciences sub sectors



AnteoTech does not operate here




Note: Chemiluminescent immunoassays = CLIA, Enzyme-linked immunosorbent assay = ELISA, Fluorescent Immunoassays = FIA

Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company

# AnteoTech's Life Sciences Markets & Growth Potential AnteoTech

All figures in US\$ Billions, as at 2024



Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company

# Our Applications – Now and New Opportunities

## 1. Multiplex Activation kit

- **Sales to the Serum Institute of India** for use in their Luminex in-house vaccine quality control tests.
  - Three out of every four children worldwide receive at least one of the Serum Institute's vaccines during their lifetime.



## 2. AnteoBind™ NXT

- **Lower cost, higher performing (more sensitive & reproducible) immunodiagnostic tests, across multiple lateral flow platforms, chemiluminescence (CLIA) particle & ELISA plate formats.**
- **Securing a greater proportion of product value, as a core ingredient**




ELISA plates



CLIA particles

## 3. AnteoBind™ Biosensor

- Supporting the development of **next-generation immunodiagnostic tests.**
- **Compatible with a range of test detection formats** including optical and electrical sensors. Below has **AnteoBind™ NXT inside.**




*C-reactive protein (CRP) serves as a vital biomarker for the real-time monitoring of inflammation, infections, and cardiovascular diseases, a sensitive and selective electrochemical immunosensor is developed for the noninvasive detection of CRP on a thin film – AnteoBind NXT™ has been used to Improve sensitivity of detection.*

# Bioconjugation is AnteoTech's specialisation!

- **Biomolecules**<sup>1</sup> are the fundamental building blocks of living organisms and essential to biological functions.
- The process of attaching biomolecules to other molecules or surfaces is known as **Bioconjugation**.
- Bioconjugation is a key step in diagnostics. It allows disease markers<sup>1</sup> to be captured and visualised using different assay techniques. Billions of diagnostic tests are performed globally every year.
- **AnteoBind™ NXT preferentially attaches antibodies to surfaces:**
  - Improving antibody orientation, maximising assay sensitivity and minimising test antibody and other material usage (antibodies can comprise (35 to 70)% of test costs)

<sup>1</sup>= proteins including antibodies, nucleic acids, carbohydrates and lipids


## How AnteoBind™ NXT coated surfaces improve antibody orientation



Source: Company data, January 2026 ©

# AnteoBind NXT's Competitive Advantages in Immunoassays are Significant

- ✓ **Superior Performance:**
  - Up to a *45 x* improvement in assay performance (assay signal increase)
- ➔ **Simplified Workflow:**
  - *One-step* activation process at room temperature
- 🐷 **Cost Optimisation:**
  - Up to *90% reduction* in antibody requirements
- 🕒 **Extended Stability:**
  - A single particle can be used multiple times for up to *12 months* post activation
- ⚙️ **Enhanced Compatibility and Specificity:**
  - Enables *higher specificity* conjugation of challenging biomolecules
- 🗑️ **Reduced Wastage:**
  - Staged workflow, versus *all-in-one* processes with short 'use by' timeframes.




# AnteoBind™ NXT Supports a Range of Bioconjugations

- **Antibodies** (e.g., mouse/human IgG, IgM)
- **Viral particles** (e.g., HAV)
- **Virus like particles** (e.g., Flavivirus)
- **Antigen** (e.g., COVID-19 spike proteins)
- **Binding proteins** (e.g., Streptavidin, Protein G/A)
- **Serum protein** (e.g., BSA)
- **Polysaccharide** (e.g., Polysialic acid)
- **Synthetic polymers** (e.g., Polyacrylic acid)
- **Particle to particle** (e.g., Qdots to nanoparticles)

Can be:-

- **Nucleic acids** (e.g., single-strand DNA, poly-Ts)




# Progress Update

- The key factors in market growth, uptake and progress are:
  - Testing needs to be undertaken to align with specific application needs
    - **Minimum** timeframe from sample receipt to results: 2 months
  - Uptake/Adoption is critically dependent on stage in the product cycle (regulation related)
    - **New products** versus established product (switching costs)
- AnteoBind™ NXT's sales pipeline has grown significantly over the past six months:
  - More evaluations are underway across Europe, North America, India and Asia than at any time in recent years
  - Driven by targeted sales campaigns, structured sales processes/sales support, conference participation and new marketing materials (2 x "White Papers" – Lateral Flow & CLIA)
  - Progress has been made re-engaging with large global life sciences companies in relation to joint product development and commercialisation and direct product supply
  - On 3 March 2026, the first phase of a joint CLIA product development program using AnteoBind™ NXT, in collaboration with a large global life sciences company, was announced on the ASX<sup>2</sup>
- Potential entry into the CLIA and ELISA markets is under assessment and in early planning stages

<sup>2</sup> = ASX release dated 3 March 2026 "Collaborative New Immunoassay Product Development Program"

# In terms of potential CLIA market entry

Novel AnteoBind™ NXT activation of magnetic particles delivers greater sensitivity and reproducibility (1.8 x improved CLIA signals, relative to Tosyl-activated particles), 1.5 to 6 x lower antibody usage along with 6 x faster activation<sup>4</sup>



CLIA Consumables Breakdown

	Ranges [%]
Antibodies	(40 to 60)
Particles	(15 to 30)
Other e.g. Equipment, Services, Reagents	(45 to 10)
Total	100

Source: In-house testing data

Global CLIA market (2024): US\$13 billion<sup>3</sup>  
 (Consumables x 66%  
 Particles x 20% (ave.))  
**~ US\$1.7 billion**

“Pilot Market” entry under assessment/ in early planning stages

Source: Grand View Research, Chemiluminescence Immunoassay Market (2024–2030); <https://www.grandviewresearch.com/industry-analysis/chemiluminescence-immunoassay-market>

Here AnteoTech could move “up the value chain” and secure a greater proportion of product value as a core component

<sup>3</sup> = Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company. Refer Page 6. of this presentation  
<sup>4</sup> = Source: AnteoTech Ltd technical “White Paper” entitled: Enhancing CLIA Performance: A Comparative study. AnteoBind™ NXT vs Tosyl-activated magnetic particle. [www.anteotech.com](http://www.anteotech.com)

# Who already uses AnteoBind™ and works with us?



## Distributors



## Research Partners



# Summary

- AnteoBind™ advances immunodiagnostics through surface chemistry modification
  - Fast, enabled by its unique, proprietary chemistry
  - Supports lower cost end use applications through reduced antibody usage, by minimising waste and improving workflows
  - Delivers improved test performance. Through greater sensitivity and more reliable and reproducible results.
- Strategic Focus areas:-
  - Luminex and Lateral flow: Building a global presence
  - CLIA – Collaborating/commercialising underpinning further sales
  - ELISA – Collaborating/commercialising
  - Biosensors opportunities and more, e.g. Immunoprecipitation
- Ensuring AnteoTech secures a greater proportion of product value as a core component

**Go to [www.anteotech.com](http://www.anteotech.com)  
to request a copy of our  
CLIA and Lateral Flow/Luminex  
“White Papers”**

# Questions?

## Contact:

**Merrill Gray**

[merrill.gray@anteotech.com](mailto:merrill.gray@anteotech.com)

+61 (07) 3219 0085

[www.anteotech.com](http://www.anteotech.com)

# Want to know more about our Technology?



LINK:

<https://www.youtube.com/watch?v=gaCM0wokQLI>

